Liu Yuyao, Wu Yuanqiang, Wu Fang, Hu Chunhong
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Chemotherapy. 2022;67(4):248-252. doi: 10.1159/000525623. Epub 2022 Jun 28.
There is no standard therapy for nonsmall-cell lung cancer harboring rare coexistent EGFR mutations. Here, we report a female patient who was diagnosed as lung adenocarcinoma with three mutations of G724S, E709K, and V689I in exon 18. The patient responded to, but also showed rapid development of resistance to multiple therapies, including a second-generation EGFR-TKI of afatinib, a platinum-based doublet chemotherapy, and a multiple target TKI of anlotinib. As such, she ended up with a short overall survival time. Further research is required to understand the resistance mechanism(s) of these complex gene mutations.
对于伴有罕见共存表皮生长因子受体（EGFR）突变的非小细胞肺癌，目前尚无标准治疗方案。在此，我们报告一名女性患者，她被诊断为肺腺癌，其第18外显子存在G724S、E709K和V689I三种突变。该患者对包括第二代EGFR酪氨酸激酶抑制剂（TKI）阿法替尼、铂类双联化疗以及多靶点TKI安罗替尼在内的多种治疗有反应，但也迅速出现耐药，最终总生存时间较短。需要进一步研究以了解这些复杂基因突变的耐药机制。
